🇺🇸 FDA
Patent

US 11135283

Retroviral vector for the administration and expression of replicon RNA expressing heterologous nucleic acids

granted A61KA61K39/21A61P

Quick answer

US patent 11135283 (Retroviral vector for the administration and expression of replicon RNA expressing heterologous nucleic acids) held by IMMUNE DESIGN CORP. expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
IMMUNE DESIGN CORP.
Grant date
Tue Oct 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K39/21, A61P, A61P31/12